Celldex Therapeutics CLDX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's additional paid-in capital?
- Celldex Therapeutics (CLDX) reported additional paid-in capital of $2.35B in Q1 2026.
- How has Celldex Therapeutics's additional paid-in capital changed year-over-year?
- Celldex Therapeutics's additional paid-in capital increased by 1.6% year-over-year, from $2.31B to $2.35B.
- What is the long-term trend for Celldex Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Celldex Therapeutics's additional paid-in capital has grown at a 12.8% compound annual growth rate (CAGR), from $1.28B to $2.34B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.